Literature DB >> 9360010

Pinaverium acts as L-type calcium channel blocker on smooth muscle of colon.

J Malysz1, L A Farraway, M O Christen, J D Huizinga.   

Abstract

The effect of pinaverium was electrophysiologically characterized and compared with the established L-type calcium channel blockers diltiazem, D600, and nitrendipine on canine colonic circular smooth muscle. Effects were studied on the electrical activity of the smooth muscle cells, in particular the spontaneously occurring slow wave. In addition, effects were examined on spontaneous contraction patterns and contractile activities generated by stimulation of cholinergic nerves or directly by stimulating muscarinic receptors. Effects were also examined on excitation of NO-releasing intrinsic nerves. Pinaverium bromide affected the slow wave by selectively inhibiting the plateau potential that is associated with generation of contractile activity. Pinaverium, similar to diltiazem and D600, produced reductions in cholinergic responses as well as spontaneous contractions. The IC50 values for inhibition of cholinergic responses for pinaverium, diltiazem, and D600 were 1.0 x 10(-6), 4.1 x 10(-7), and 5.3 x 10(-7) M, respectively. The IC50 values for inhibition of spontaneous contractile activity for pinaverium, diltiazem, and D600 were 3.8 x 10(-6), 9.7 x 10(-7), and 8.0 x 10(-7) M, respectively. Increases in contractility by carbachol were abolished by pretreatment with either pinaverium or D600. In addition, neither pinaverium nor D600 had any effects on the inhibitory NO-mediated relaxations. These data provide a rationale for the use of pinaverium in the treatment of colonic motor disorders where excessive contraction has to be suppressed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360010     DOI: 10.1139/cjpp-75-8-969

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  5 in total

1.  T-type Ca(2+) channel modulation by otilonium bromide.

Authors:  Peter R Strege; Lei Sha; Arthur Beyder; Cheryl E Bernard; Edward Perez-Reyes; Stefano Evangelista; Simon J Gibbons; Joseph H Szurszewski; Gianrico Farrugia
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-03-04       Impact factor: 4.052

Review 2.  Role of antispasmodics in the treatment of irritable bowel syndrome.

Authors:  Anita Annaházi; Richárd Róka; András Rosztóczy; Tibor Wittmann
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

3.  Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial.

Authors:  Liang Zheng; Weimin Lu; Qi Xiao; Yaoliang Lai; Heng Fan; Yuling Sun; Dawei Huang; Yuanyuan Wang; Zhen Li; Zhengyan Jiang; Xingxing Liu; Lijuan Zhang; Dongmei Zuo; Zhexing Shou; Qing Tang; Huisuo Huang; Yongqiang Yang; Zongxiang Tang; Jun Xiao
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

4.  Effects of Fengliao-Changweikang in Diarrhea-predominant Irritable Bowel Syndrome Rats and Its Mechanism Involving Colonic Motility.

Authors:  Mengdi Jia; Xiaofang Lu; Zhengfang Wang; Luqing Zhao; Shengsheng Zhang
Journal:  J Neurogastroenterol Motil       Date:  2018-07-30       Impact factor: 4.924

5.  Efficacy of the Combination of Pinaverium Bromide 100 mg Plus Simethicone 300 mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial.

Authors:  Max J Schmulson; Jazmin Chiu-Ugalde; Adolfo Sáez-Ríos; Aurelio López-Colombo; Gualberto J Mateos-Pérez; José María Remes-Troche; Sergio Sobrino-Cossio; Julio C Soto-Pérez; José L Tamayo de la Cuesta; Oscar T Teramoto-Matsubara; Juan C López-Alvarenga
Journal:  J Clin Gastroenterol       Date:  2020-04       Impact factor: 3.174

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.